In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|January 9, 2008
Apitope MS Vaccine Shows Promise
Author(s)BioPharm International Editors
Apitope Technology Ltd. (Bristol, UK), has announced the completion of dosing for all six multiple sclerosis (MS) patients in a Phase 1/2a trial of ATX-MS-1467
Advertisement
Apitope Technology Ltd. (Bristol, UK), has announced the completion of dosing for all six multiple sclerosis (MS) patients in a Phase 1/2a trial of ATX-MS-1467. The therapeutic vaccine was found to be safe and well tolerated in secondary progressive multiple sclerosis (SPMS) patients.
Although efficacy was not an endpoint of this trial, one patient, with optic neuritis resulting from the neuroinflammatory process involved in MS, did demonstrate a clinically significant improvement in visual acuity post treatment. This was demonstrated in analysis of the initial visual acuity examination at screening compared to the one-month follow up test.
The ATX-MS-1467 Phase 1/2a open label trial was designed as a dose-escalation study to assess the safety and tolerability with all six patients receiving five escalating doses given seven to 14 days apart of 25, 50, 100, 400, and 800 µg followed by a repeat of the 800 µg dose.
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
2
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5